Keyword: Alunbrig (brigatinib)
After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.
U.S. medtech exports to China are targets in trade war; Alunbrig beats Xalkori in 1st-line lung cancer; FDA blasts Huahai for careless process changes.
Pfizer’s about to get even more competition in ALK-positive lung cancer. And if new data are any indication, it’s pretty stiff.
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
Takeda needs to replace sinking Velcade revenue, but it has just three late-stage drugs while Shire has about a dozen.
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
Takeda's Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche—but some new data could help change that.
After a bruising two-day play-in, Taltz and Nerlyx are among the victors in our first round of this year’s drug name tournament challenge.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Roche's Alecensa nabbed a new FDA approval to treat first-line lung cancer, putting it on even footing with Pfizer's Xalkori and Novartis' Zykadia.